PharmAust Limited (ECQ.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR

Add to watchlist

0.1020

+0.0030

(+3.03%)

As of 08:10AM CEST. Market open.

Loading interactive chart…

PR Newswire
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company"), a clinical-stage biotechnology company, is pleased to announce that it has met its primary safety and tolerability endpoints with monepantel (MPL) and, importantly, demonstrated a positive signal of potential efficacy. Rates of disease progression in patients with Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) measured by changes in ALSFRS-R may be slowed by 58% for Cohort 2, when compared to an external cont
Simply Wall St.
PharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week alone
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
Simply Wall St.
PharmAust Full Year 2023 Earnings: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)
PharmAust ( ASX:PAA ) Full Year 2023 Results Key Financial Results Revenue: AU$3.90m (down 14% from FY 2022). Net loss...